A5055848565- Immunotherapy and Immune Responses
- Lung Cancer Treatments and Mutations
- RNA modifications and cancer
- Epigenetics and DNA Methylation
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Monoclonal and Polyclonal Antibodies Research
- interferon and immune responses
- Bacteriophages and microbial interactions
- Cancer Genomics and Diagnostics
- Peptidase Inhibition and Analysis
- Ferroptosis and cancer prognosis
- SARS-CoV-2 and COVID-19 Research
- Metastasis and carcinoma case studies
- Lung Cancer Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Gastric Cancer Management and Outcomes
- Immune Cell Function and Interaction
- Cancer Diagnosis and Treatment
- Immune cells in cancer
- Cancer Research and Treatments
- Cancer Mechanisms and Therapy
- Cancer-related molecular mechanisms research
- Chromatin Remodeling and Cancer
- Protein Degradation and Inhibitors
Institut Català d'Ornitologia
2020-2024
Institut Català d'Oncologia
2014-2024
Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
2021-2024
Dana-Farber Cancer Institute
2020-2023
Hospital Universitari Germans Trias i Pujol
2021-2023
Josep Carreras Leukaemia Research Institute
2020-2021
Institut d'Investigació Biomédica de Bellvitge
2015-2020
Ajuntament de L’Hospitalet
2019
Duran i Reynals Hospital
2016-2019
Bellvitge University Hospital
2017
Abstract Small cell lung carcinoma (SCLC) is highly mutated, yet durable response to immune checkpoint blockade (ICB) rare. SCLC also exhibits cellular plasticity, which could influence its immunobiology. Here we discover that a distinct subset of uniquely upregulates MHC I, enriching for ICB benefit. In vitro modeling confirms epigenetic recovery I in following loss neuroendocrine differentiation, tracks with derepression STING. Transient EZH2 inhibition expands these nonneuroendocrine...
Abstract Purpose: Lung cancer remains as the leading cause of cancer-related death worldwide, mainly due to late diagnosis. Cytology is gold-standard method for lung diagnosis in minimally invasive respiratory samples, despite its low sensitivity. We aimed identify epigenetic biomarkers with clinical utility minimally/noninvasive specimens improve accuracy current technologies. Experimental Design: The identification novel stage I tumors was accomplished using an integrative genome-wide...
Abstract Purpose: The blockade of immune checkpoints such as PD-L1 and PD-1 is being exploited therapeutically in several types malignancies. Here, we aimed to understand the contribution genetics lung cancer ability tumor cells escape immunosurveillance checkpoints. Experimental Design: More than 150 primary non–small cell cancers, including pulmonary sarcomatoid carcinomas, were tested for levels HLA-I complex, PD-L1, tumor-infiltrating CD8+ lymphocytes, alterations main genes....
Abstract Despite the genetic inactivation of SMARCA4 , a core component SWI/SNF-complex commonly found in cancer, there are no therapies that effectively target SMARCA4-deficient tumours. Here, we show that, unlike cells with activated MYC oncogene, refractory to histone deacetylase inhibitor, SAHA, leading aberrant accumulation H3K27me3. -mutant also an impaired transactivation and significantly reduced levels demethylases KDM6A/UTX KDM6B/JMJD3, strong dependency on these demethylases, so...
Abstract Immunotherapy has shown limited efficacy in patients with EGFR-mutated lung cancer. Efforts to enhance the immunogenicity of cancer have been unsuccessful date. Here, we discover that MET amplification, most common mechanism resistance third-generation EGFR tyrosine kinase inhibitors (TKI), activates tumor cell STING, an emerging determinant (1). However, STING activation was restrained by ectonucleosidase CD73, which is induced MET-amplified, EGFR-TKI–resistant cells. Systematic...
Elucidating the adaptive mechanisms that prevent host immune response in cancer will help predict efficacy of anti-programmed death-1 (PD1)/L1 therapies. Here, we study cell-intrinsic lung (LC) to interferon-γ (IFNγ), a cytokine promotes immunoresponse and modulates programmed death-ligand 1 (PD-L1) levels. We report complete refractoriness IFNγ subset LCs as result JAK2 or IFNGR1 inactivation. A submaximal affects another shows constitutive low levels IFNγ-stimulated genes (IγSGs) coupled...
Diabetes is related with increased cancer mortality across multiple types. Its role in lung still unclear. We aim to determine the prognostic value of fasting plasma glucose (FPG) and diabetes mellitus patients locally advanced non-small cell (NSCLC) treated concurrent chemoradiotherapy.One-hundred seventy stage III NSCLC received definitive chemoradiotherapy from 2010 2014. Clinico-pathological data clinical outcome was retrospectively registered. Fifty-six (33%), met criteria for type 2...
ObjectivesImmune checkpoint inhibitors (ICIs) have provided a breakthrough in the treatment of non-small cell lung cancer (NSCLC) patients, but only some patients benefit substantively. Identifying definitive predictive biomarkers could overcome this limitation.Materials and methodsWe selected 146 metastatic NSCLC treated with anti-PD-(L)1. Immunohistochemistry HLA-I, PD-L1 CD73 was performed 122 tumor biopsies at diagnosis. The association parameters, value to ICI were determined.ResultsIn...
Patients with lung cancer are at increased risk of SARS-CoV-2 infection and severe complications from COVID-19, but information on the efficacy anti-SARS-CoV-2 vaccine in these patients is scarce. We aimed evaluating safety immunogenicity COVID-19 vaccines this population.The prospective, nationwide SOLID substudy, enrolled adults who were fully vaccinated against COVID-19. Serum IgG antibody levels quantitatively assessed two weeks six months after receipt last dose using a chemiluminescent...
// Marta Domènech 1 , 3 Ana M. Muñoz Marmol 2 Jose Luis Mate Anna Estival Teresa Moran Marc Cucurull Maria Saigi Ainhoa Hernandez Carolina Sanz Alba Hernandez-Gallego Aintzane Urbizu Martinez-Cardus Adrià Bernat and Enric Carcereny Medical Oncology Department, Catalan Institute of Badalona, Germans Trias i Pujol Hospital, Barcelona, Spain Pathology Badalona Applied Research Group in (BARGO), Institut d'Investigació en Ciències de la Salut (IGTP),...
Abstract Background There is a lack of useful diagnostic tools to identify EGFR mutated NSCLC patients with long-term survival. This study develops prognostic model using real world data assist clinicians predict survival beyond 24 months. Methods stage IIIB and IV diagnosed between January 2009 December 2017 included in the Spanish Lung Cancer Group (SLCG) thoracic tumor registry. Long-term was defined as being alive months after diagnosis. A multivariable carried out binary logistic...
Approximately 20% of lung adenocarcinomas harbor activating mutations at KRAS, an oncogene with the ability to alter tumor immune microenvironment. In this retrospective study, we examined 103 patients KRAS-mutant adenocarcinoma who were treated immunotherapy-based regimens and evaluated clinical outcomes according PD-L1 expression type KRAS mutation. Among all included, 47% carried G12C mutation whereas 53% harbored non-G12C mutations. status was available for 77% cases, higher among tumors...
Background: Primary cardiac tumors are extremely rare; most myxomas with a benign prognosis. However, primary sarcomas highly aggressive and treatment options limited. Radical surgery is often not feasible conventional therapies provide only modest results. Due to the rare nature of tumors, there no proper randomized studies guide treatment. Their complexity requires alternative approaches in order improve efficacy. Methods: We isolated DNA from 5 sarcomas; quality 3 them was sufficient...
BACKGROUND: The National Lung Screening Trial (ILST) and the NELSON study showed that lung cancer-specific mortality can be reduced by 20-24% using low-dose computed tomography (LDCT) screening in high-risk populations, due to an increase early-stage diagnoses. RESEARCH QUESTION: How much cancer-related direct costs may a LDCT programme based on ILST protocol public healthcare system?STUDY DESIGN AND METHODS: Cost analysis of cancer (LCS) vs. usual care framework retail price Catalan system....